Expression of VEGF in human conjunctival melanoma analyzed with immunohistochemistry.

Expression of VEGF in human conjunctival melanoma analyzed with immunohistochemistry.

Publication date: Dec 13, 2018

The aim of this study was to examine the immunolocalization of VEGF-A and CD34, a marker of endothelial cells, in human conjunctival melanoma.

This study retrospectively analyzed primary conjunctival melanoma patients who underwent surgical resection of the tumor. All excised tissues were fixed with paraformaldehyde and embedded in paraffin, which were then submitted for immunohistochemistry with anti-VEGF and CD34 antibodies.

The study sample comprised 4 female and two male melanoma patients. The age of the patients ranged from 64 to 84 (average age, 73) years. Histopathology of the surgically resected tumor tissues demonstrated accumulation of polygonal atypical malignant cells producing melanin. Cytoplasmic immunoreactivity for VEGF was clearly observed in tumor cells of all six tumors. In contrast, CD34-positive endothelial cells were less marked in the melanoma tissues than in the adjacent noncancerous subconjunctival stroma.

VEGF immunoreactivity was observed in conjunctival melanoma tissues, in which endothelial cells were hardly observed. These results suggest that although VEGF is expressed, conjunctival melanoma is a hypovascular tumor.

Open Access PDF

Kase, S., , Kikuchi, and Ishida, S. Expression of VEGF in human conjunctival melanoma analyzed with immunohistochemistry. 22266. 2018 Clin Ophthalmol (12):

Concepts Keywords
Antibodies Antibodies
CD34 Melanoma
Conjunctival Conjunctiva
Endothelial Primary conjunctival melanoma
Endothelial Cells Branches of biology
Histopathology Surgical resection tumor
Immunohistochemistry Tumor tumors
Immunoreactivity Surgically resected tumor
Malignant Conjunctival melanoma
Melanin
Melanoma
Paraffin
Stroma
Surgical Resection
Tumor
VEGF

Semantics

Type Source Name
gene UNIPROT FLT1
gene UNIPROT FBXW11
gene UNIPROT TBX5
gene UNIPROT DUOXA1
gene UNIPROT AKT1
drug DRUGBANK Gefitinib
gene UNIPROT EGR3
disease DOID lymphoma
disease MESH lymphoma
disease MESH squamous carcinomas
drug DRUGBANK Emodepside
gene UNIPROT INTU
gene UNIPROT BRD2
gene UNIPROT MBNL1
gene UNIPROT ZBTB8OS
disease DOID malignant tumor
gene UNIPROT CTNND1
gene UNIPROT CSE1L
gene UNIPROT BCAR1
disease MESH eye diseases
disease MESH Visual
disease MESH multiple
disease MESH recurrence
disease DOID uveal melanoma
disease MESH uveal melanoma
disease DOID age related macular degeneration
disease MESH age related macular degeneration
drug DRUGBANK Ranibizumab
drug DRUGBANK Bevacizumab
gene UNIPROT SSRP1
disease MESH pathological neovascularization
gene UNIPROT SNAP25
gene UNIPROT HERPUD1
gene UNIPROT NR1H4
gene UNIPROT ADRB2
gene UNIPROT BFAR
drug DRUGBANK Esomeprazole
gene UNIPROT PNMA2
drug DRUGBANK Sulodexide
gene UNIPROT FOXD3
gene UNIPROT LSAMP
gene UNIPROT LAMP3
gene UNIPROT TNFSF14
drug DRUGBANK D-Alanine
gene UNIPROT TNMD
gene UNIPROT CYLD
drug DRUGBANK Tretamine
gene UNIPROT MBOAT4
drug DRUGBANK Hydrogen peroxide
drug DRUGBANK Phosphoric acid
gene UNIPROT TSPO
gene UNIPROT CHRM3
gene UNIPROT SUCO
gene UNIPROT OPTC
gene UNIPROT TENM1
disease DOID conjunctival nevus
gene UNIPROT IRF1
gene UNIPROT CEP55
disease DOID noma
disease MESH noma
gene UNIPROT COL9A3
gene UNIPROT COMP
gene UNIPROT COL9A1
gene UNIPROT COL9A2
gene UNIPROT SCN8A
disease MESH tumorigenesis
pathway BSID Angiogenesis
pathway BSID Apoptosis
disease MESH tumor escape
drug DRUGBANK Oxygen
disease MESH growth
drug DRUGBANK Natural alpha interferon
disease MESH metastases
disease MESH nevus
gene UNIPROT PAM
gene UNIPROT MYCBP2
disease MESH melanosis
gene UNIPROT ASAH1
gene UNIPROT PHPT1
gene UNIPROT SOX3
drug DRUGBANK Coenzyme M
pathway BSID Melanoma
disease DOID melanoma
disease MESH melanoma
drug DRUGBANK Formaldehyde
disease MESH tumor
gene UNIPROT CD34
gene UNIPROT DNMT1
gene UNIPROT CD69
gene UNIPROT CD5L
disease DOID conjunctival melanoma
gene UNIPROT VEGFA

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *